✦ LIBER ✦

A positron emission tomography (PET) study of cerebral dopamine D2and serotonine 5-HT2Areceptor occupancy in patients treated with cyamemazine (Tercian)

✍ Scribed by Y. Hodé; M. Reimold; A. Demazières; G. Reischl; F. Bayle; P. Nuss; A. Hameg; M. Dib; J. P. Macher

Publisher: Springer
Year: 2005
Tongue: English
Weight: 160 KB
Volume: 180
Category: Article
ISSN: 0033-3158
DOI: 10.1007/s00213-005-2172-z

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Active cyamemazine metabolites in patien

Active cyamemazine metabolites in patients treated with cyamemazine (Tercian®): influence on cerebral dopamine D2and serotonin 5-HT2Areceptor occupancy as measured by positron emission tomography (PET)

✍ Yann Hodé; Amine Benyamina; Christophe Arbus; Matthias Reimold 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 251 KB

Dopamine D2receptor occupancy by perospi

Dopamine D2receptor occupancy by perospirone: a positron emission tomography study in patients with schizophrenia and healthy subjects

✍ Ryosuke Arakawa; Hiroshi Ito; Akihiro Takano; Masaki Okumura; Hidehiko Takahashi 📂 Article 📅 2010 🏛 Springer 🌐 English ⚖ 159 KB

Occupancy of dopamine D2and D3and seroto

Occupancy of dopamine D2and D3and serotonin 5-HT1Areceptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography

✍ Nicholas Seneca; Sjoerd J. Finnema; István Laszlovszky; Béla Kiss; Attila Horvát 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 323 KB

Long-term changes of striatal dopamine D

Long-term changes of striatal dopamine D2 Receptors in patients with Parkinson's disease: A study with positron emission tomography and [11C]Raclopride

✍ Angelo Antonini; Johannes Schwarz; Wolfgang H. Oertel; Oliver Pogarell; Prof. Kl 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 574 KB

## Abstract We used [^11^C]raclopride (RACLO) and positron emission tomography (PET) to study longitudinally striatal dopamine D~2~ receptor binding in nine patients with Parkinson's disease (PD) at an early drug‐naive stage and 3–5 years later, when motor fluctuations had appeared in seven of them